Your browser doesn't support javascript.
loading
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Lheureux, Stephanie; Cristea, Mihaela C; Bruce, Jeffrey P; Garg, Swati; Cabanero, Michael; Mantia-Smaldone, Gina; Olawaiye, Alexander B; Ellard, Susan L; Weberpals, Johanne I; Wahner Hendrickson, Andrea E; Fleming, Gini F; Welch, Stephen; Dhani, Neesha C; Stockley, Tracy; Rath, Prisni; Karakasis, Katherine; Jones, Gemma N; Jenkins, Suzanne; Rodriguez-Canales, Jaime; Tracy, Michael; Tan, Qian; Bowering, Valerie; Udagani, Smitha; Wang, Lisa; Kunos, Charles A; Chen, Eric; Pugh, Trevor J; Oza, Amit M.
Afiliação
  • Lheureux S; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Cristea MC; City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Bruce JP; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Garg S; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Cabanero M; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Mantia-Smaldone G; Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Olawaiye AB; UPMC Mercy, Pittsburgh, PA, USA.
  • Ellard SL; BC Cancer Kelowna, Kelowna, BC, Canada.
  • Weberpals JI; Ottawa Regional Cancer Center, Ottawa, ON, Canada.
  • Wahner Hendrickson AE; Mayo Clinic Cancer Center, Rochester, MN, USA.
  • Fleming GF; University of Chicago, Chicago, IL, USA.
  • Welch S; London Regional Cancer Program, London, ON, Canada.
  • Dhani NC; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Stockley T; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Rath P; Ontario Institute for Cancer Research, Toronto, ON, Canada.
  • Karakasis K; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Jones GN; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Jenkins S; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Rodriguez-Canales J; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Tracy M; Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Tan Q; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Bowering V; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Udagani S; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Wang L; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Kunos CA; National Cancer Institute, Bethesda, MA, USA.
  • Chen E; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Pugh TJ; Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Oza AM; Princess Margaret Cancer Centre, Toronto, ON, Canada. Electronic address: amit.oza@uhn.ca.
Lancet ; 397(10271): 281-292, 2021 01 23.
Article em En | MEDLINE | ID: mdl-33485453
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Pirazóis / Pirimidinonas / Desoxicitidina / Inibidores Enzimáticos / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials Limite: Female / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Pirazóis / Pirimidinonas / Desoxicitidina / Inibidores Enzimáticos / Antimetabólitos Antineoplásicos Tipo de estudo: Clinical_trials Limite: Female / Humans / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2021 Tipo de documento: Article